Why P2B001

Publications & Presentations

P2B001 Publications
  1. Falconer D et al. Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a Phase 3 randomized, controlled trial. Poster presented at: International Congress of Parkinson’s Disease and Movement Disorders ®; August 2023; Copenhagen, Denmark.
  2. Lawrence W. Elmer et al. P2B001 significantly reduced risk of daytime sleepiness: results from a randomized controlled phase 3 trial with active pramipexole arm in early Parkinson’s disease (PD). Poster presented at: AAN Annual Meeting; April 2023; Boston, USA.
  3. Olanow CW et al. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941.
  4. Hauser RA et al. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2.
  5. Olanow WG. Efficacy and safety of P2B001 in the management of early Parkinson’s disease. Results from a phase 3, randomized, double-blind, double-dummy controlled trial.
  6. Olanow WG. P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial.
P2B001 Presentations
  1. Patient outcomes with P2B001: Phase 3 top-line results. Prof. C Warren Olanow
  2. Why we need more treatment options for early-stage Parkinson’s disease? Prof. Robert A. Hauser

Thank you!

An email was sent with access to our exclusive materials.
Please check your inbox and spam folder.

Please subscribe for this

Get this exclusive content straight to your email